As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.
If you are not happy with the results below please do another search
50 search results for:
Indonesia is in talks with several African countries, including Nigeria, to export and donate its homemade COVID-19 vaccine, its developer said on Friday, after becoming the first country in Southeast Asia to approve a domestically developed COVID shot.
A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday.
The Nasdaq-listed company and Australia’s Victoria state said they signed a partnership to create a centre, which would run clinical research of experimental messenger ribonucleic acid, or mRNA, vaccines and therapies with the aim of attracting experts from around the world.
The alliance will combine this technology with Boehringer’s research and development expertise to develop a first-in-class treatment for patients with eye diseases, Surrozen announced.
Chaudhary joins imre with more than two decades of experience leading top holding company agencies and practices and advising global clients across all industries with deep expertise for clients invested in healthcare across pharmaceutical, biotech, medical device, health tech, consumer health, payor and health systems.
An estimated 2.55 million U.S. middle and high school students reported using e-cigarettes during the early part of this year, health officials said on Thursday, a level they described as concerning.
TauRx announced preliminary results Thursday from the Phase III LUCIDITY study, showing hydromethylthionine mesylate (HMTM), an inhibitor of tau aggregates, could slow Alzheimer’s disease progression or cognitive decline.
Provention Bio entered a co-promotion agreement with Sanofi Thursday ahead of the possible November approval of Type 1 diabetes drug teplizumab.
Eli Lilly and Co. said on Thursday the U.S. Food and Drug Administration (FDA) had agreed to a quick review of its diabetes drug Mounjaro to treat obesity, months after a study showed it helped people lose more than 20% of their weight.